We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > trichomoniasis

News List

Lupin gets USFDA approval of sNDA for SOLOSEC (secnidazole) to treat trichomoniasis expresspharma
July 02, 2021
SOLOSEC demonstrated a 92.2 per cent clinically and statistically significant cure rate for patients with trichomoniasis based on a landmark Phase 3 clinical trial.
Lupin announces FDA filing acceptance of sNDA for Solosec to treat trichomoniasis pharmaceutical-business-review
November 18, 2020
Lupin Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents.
Lupin presents Phase 3 data for Solosec in female patients with trichomoniasis expresspharma
August 17, 2020
The company plans to submit a supplemental New Drug Application for Solosec to the FDA for the treatment of trichomoniasis later this year.
Lupin announces results of Phase 3 study of Single-Dose Solosec for treatment of trichomoniasis expresspharma
May 05, 2020
Primary endpoint successfully achieved in Phase 3 clinical trial of 147 patients.